20,200 results match your criteria Implantable Cardioverter-Defibrillators

Long-term cardiac monitoring after embolic stroke of undetermined source. Search longer - look harder.

Am J Med 2022 May 14. Epub 2022 May 14.

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address:

Embolic stroke of undetermined source (ESUS) represents a heterogeneous subgroup of patients with cryptogenic stroke, in which despite an extensive diagnostic work-up the cause of stroke remains uncertain. Identifying covert atrial fibrillation among ESUS patients remains challenging. The increasing use of cardiac implanted electronic devices (CIED), such as pacemakers, implantable defibrillators and implantable loop recorders (ILR), has provided important information on the burden of subclinical atrial fibrillation. Read More

View Article and Full-Text PDF

Myocardial ATP depletion detected noninvasively predicts sudden cardiac death risk in heart failure patients.

JCI Insight 2022 May 17. Epub 2022 May 17.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, United States of America.

Background: Sudden cardiac death (SCD) remains a worldwide public health problem in need of better noninvasive predictive tools. Current guidelines for primary preventive SCD therapies such as implantable cardioverter defibrillators (ICDs) are based on left ventricular ejection fraction (LVEF), but these are imprecise with fewer than 5% of ICDs delivering life-saving therapy per year. Impaired cardiac metabolism and ATP depletion cause arrhythmias in experimental models, but a link between arrhythmias and cardiac energetic abnormalities in people has not been explored, nor the potential for metabolically predicting clinical SCD risk. Read More

View Article and Full-Text PDF

[Management of infections in patients with cardiac implantable electronic devices].

G Ital Cardiol (Rome) 2022 May;23(5):328-335

Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste.

Implantation of pacemakers and cardiac defibrillators is a life-saving treatment but can put our patients at risk of infections, increasing morbidity and mortality and prolonging hospitalization with a significant financial healthcare burden. A preventive strategy is crucial but, while several strategies such as administration of intravenous antibiotic therapy before implantation are well recognized, other uncertainties remain. The main gaps regard the use of periprocedural measures, including antibacterial envelope to prevent device infection, the appropriate management of antithrombotic therapy before and after device implantation and timing of device reimplantation. Read More

View Article and Full-Text PDF

Long Term Follow-Up of Stereotactic Body Radiation Therapy for Refractory Ventricular Tachycardia in Advanced Heart Failure Patients.

Front Cardiovasc Med 2022 29;9:849113. Epub 2022 Apr 29.

Section of Cardiac Electrophysiology, Emory University, Atlanta, GA, United States.

Background: Initial studies of stereotactic body radiation therapy (SBRT) for refractory ventricular tachycardia (VT) have demonstrated impressive efficacy. Follow-up analyses have found mixed results and the role of SBRT for refractory VT remains unclear. We performed palliative, cardiac radio ablation in patients with ventricular tachycardia refractory to ablation and medical management. Read More

View Article and Full-Text PDF

Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment.

Cardiooncology 2022 May 12;8(1):11. Epub 2022 May 12.

Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.

Background: Anthracycline chemotherapy and thoracic radiation therapy (RT) are known causes of cardiomyopathy among cancer survivors, however, management guidelines for this population are lacking. In this study we describe our single institution management approach for cancer survivors with low left ventricular ejection fraction (LVEF) secondary to cancer treatment.

Methods: We conducted a retrospective descriptive study of childhood and young adult (CAYA) cancer survivors in the Adult Long-Term Follow-Up Clinic at Memorial Sloan Kettering Cancer Center enrolled between November 2005 and July 2019. Read More

View Article and Full-Text PDF

Deep learning-based insights on T:R ratio behaviour during prolonged screening for S-ICD eligibility.

J Interv Card Electrophysiol 2022 May 13. Epub 2022 May 13.

Cardiac Rhythm Management Research Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Background: A major predictor of eligibility of subcutaneous implantable cardiac defibrillators (S-ICD) is the T:R ratio. The eligibility cut-off of the T:R ratio incorporates a safety margin to accommodate for fluctuations of ECG signal amplitudes. We introduce a deep learning-based tool that accurately measures the degree of T:R ratio fluctuations and explore its role in S-ICD screening. Read More

View Article and Full-Text PDF

Digging Deeper: Understanding Trajectories and Experiences of Shared Decision-Making for Primary Prevention ICD Implantation.

J Card Fail 2022 May 9. Epub 2022 May 9.

Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA; Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA.

Background: Shared decision-making using a decision aid is required for patients undergoing implantation of primary prevention implantable cardioverter-defibrillators (ICD). It is unknown how much this process has impacted patients' experiences or choices. Effective shared decision-making requires an understanding of how patients make ICD decisions. Read More

View Article and Full-Text PDF

Cardiac rhythm devices in pediatric patients: Impact on family functioning and parent's health-related quality of life.

J Child Health Care 2022 May 12:13674935221085388. Epub 2022 May 12.

Children's Research Center, 30995University Children's Hospital, Zurich, Switzerland.

This study compares the impact of children's cardiac rhythm devices and health status on their parents with that of healthy controls. Furthermore, it aims to ascertain whether sociodemographic characteristics and medical data are associated with parent-reported impacts. This cross-sectional study is part of a comprehensive single-center study of long-term psychosocial outcomes in pediatric patients with pacemakers and implantable cardioverter defibrillators. Read More

View Article and Full-Text PDF

Magnetic field interactions between current consumer electronics and cardiac implantable electronic devices.

J Interv Card Electrophysiol 2022 May 10. Epub 2022 May 10.

Heart Rhythm Science Center, Minneapolis Heart Institute and Foundation, 800 E 28th St, Minneapolis, MN, 55407, USA.

Background: Electronic products, including the iPhone 12, Apple Watch Series 6, and 2nd Generation AirPods, contain magnets to facilitate wireless charging. Permanent magnets may affect CIED magnet mode features by causing pacemakers to pace asynchronously and defibrillators to suspend arrhythmia detection. This study determined if CIEDs are affected by static magnetic fields from commonly used portable electronics (PE) at any distance and intends to reinforce FDA recommendations concerning consumer PE which contain permanent magnets. Read More

View Article and Full-Text PDF

Red herring pathogenic variants: a case report of premature ventricular contraction-triggered ventricular fibrillation with an incidental pathogenic variant.

Eur Heart J Case Rep 2022 May 17;6(5):ytac115. Epub 2022 Mar 17.

Department of Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN 55905, USA.

Background: Pathogenic variants in the lamin A/C gene (LMNA) can lead to a wide range of phenotypes from dilated and arrhythmogenic cardiomyopathies and conduction abnormalities to partial lipodystrophies. This case highlights a coincidental pathogenic LMNA variant identified in a patient with sudden cardiac arrest (SCA). We demonstrate the need for careful interpretation of pathogenic variants identified in cardiomyopathy genes by highlighting a case in which a coincidental pathogenic LMNA variant was found in a patient with premature ventricular complex (PVC)-induced ventricular fibrillation (VF). Read More

View Article and Full-Text PDF

Clinical Utility of HeartLogic, a Multiparametric Telemonitoring System, in Heart Failure.

Card Fail Rev 2022 Jan 21;8:e13. Epub 2022 Apr 21.

Cardiology Service, Hospital Universitario 12 de Octubre Madrid, Spain.

Telemonitoring through multiple variables measured on cardiac devices has the potential to improve the follow-up of patients with heart failure. The HeartLogic algorithm (Boston Scientific), implemented in some implantable cardiac defibrillators and cardiac resynchronisation therapy, allows monitoring of the nocturnal heart rate, respiratory movements, thoracic impedance, physical activity and the intensity of heart tones, with the aim of predicting major clinical events. Although HeartLogic has demonstrated high sensitivity for the detection of heart failure decompensations, its effects on hospitalisation and mortality in randomised clinical trials has not yet been corroborated. Read More

View Article and Full-Text PDF
January 2022

First Report of Proton Beam Therapy in a Patient With a Left Ventricular Assist Device.

ASAIO J 2022 May 6;68(5):e84-e86. Epub 2021 May 6.

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.

A 77 year old man previously implanted with a HeartMate II left ventricular assist device (LVAD) as destination therapy and an implantable cardioverter defibrillator presented with a left upper lobe squamous cell lung cancer. Oncology determined that proton beam therapy was indicated for treatment, and a multidisciplinary team of radiation physicists, radiation oncologists, and LVAD providers developed a protocol to proceed safely. He was successfully treated with combined proton beam radiation therapy and reduced dose chemotherapy. Read More

View Article and Full-Text PDF

Predictors of primary prevention implantable cardioverter defibrillator use in heart failure with reduced ejection fraction: Impact of the predicted risk of sudden cardiac death and all-cause mortality.

Eur J Heart Fail 2022 May 3. Epub 2022 May 3.

Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Aims: Use of implantable cardioverter-defibrillators (ICD) for primary prevention of sudden cardiac death (SCD) in heart failure with reduced ejection fraction (HFrEF) is limited. We aimed to investigate barriers to ICD use in HFrEF while considering the predicted risk of mortality and SCD.

Method And Results: Patients from the SwedeHF registered in 2011-2018 and with an indication for primary prevention ICD were analyzed. Read More

View Article and Full-Text PDF

Decongestive treatment adjustments in heart failure patients remotely monitored with a multiparametric implantable defibrillators algorithm.

Clin Cardiol 2022 May 3. Epub 2022 May 3.

Cardiology and Arrhythmology Clinic, Marche Polytechnic University, "Ospedali Riuniti", Ancona, Italy.

Aims: HeartLogic algorithm combines data from multiple implantable defibrillators (ICD)-based sensors to predict impending heart failure (HF) decompensation. A treatment protocol to manage algorithm alerts is not yet known, although decongestive treatment adjustments are the most frequent alert-triggered actions reported in clinical practice. We describe the implementation of HeartLogic for remote monitoring of HF patients, and we evaluate the approach to diuretic dosing and timing of the intervention in patients with device alerts. Read More

View Article and Full-Text PDF

Factors Associated with Remote Monitoring Adherence for Cardiovascular Implantable Electronic Devices.

Heart Rhythm 2022 Apr 29. Epub 2022 Apr 29.

Department of Medicine, University of California, San Francisco, CA; San Francisco Veterans Affairs Health Care System, CA. Electronic address:

Background: Professional societies strongly recommend remote monitoring (RM) of all cardiac implantable electronic devices (CIEDs), and higher RM adherence is associated with improved patient outcomes. However, adherence with RM is sub-optimal.

Objective: To better understand factors associated with remote monitoring adherence. Read More

View Article and Full-Text PDF

Trends in Opioid Use After Cardiac Implantable Electronic Device Procedures in the United States Between 2004 and 2020.

Circulation 2022 May 2;145(19):1499-1501. Epub 2022 May 2.

Cardiovascular Division (T.M.M., D.S.F.), University of Pennsylvania, Philadelphia.

View Article and Full-Text PDF

Implantation of a cardioverter-defibrillator in an 8-kg infant: a case report and literature review.

Cardiol Young 2022 May 2:1-2. Epub 2022 May 2.

Department of Pediatric Cardiology, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

The use of an implantable cardioverter-defibrillator to prevent sudden cardiac death is an approved method. Experience is limited regarding implantation techniques in infants and low-weight children. We herein describe the implantation of an epicardial implantable cardioverter-defibrillator in a 15-month-old infant weighing 8 kg. Read More

View Article and Full-Text PDF

ICD harm and benefit: risk scores applied to the Swedish ICD-treated LQTS population.

Scand Cardiovasc J 2022 12;56(1):48-55

Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.

The use of implantable cardioverter defibrillators (ICDs) in long QT syndrome (LQTS) patients is essential in high-risk patients. However, it is sometimes used in patients without high-risk profiles for whom the expected benefit may be lower than the risk of ICD harm. Here, we evaluated ICD benefit and harm by assessing risk according to risk scores and pre-ICD clinical characteristics. Read More

View Article and Full-Text PDF
December 2022

Outcomes Following Standardized Implantable Cardioverter-defibrillator Reprogramming.

J Innov Card Rhythm Manag 2022 Apr 15;13(4):4941-4945. Epub 2022 Apr 15.

Department of Medicine, Division of Cardiology, University of Wisconsin Hospitals and Clinics, Madison, WI, USA.

Multiple randomized controlled trials have demonstrated that programming implantable cardioverter-defibrillators (ICDs) with longer detection intervals and higher detection rates results in significant reductions in the delivery of inappropriate therapy without increasing the number of adverse events. Despite these findings, however, implementation of this evidence-based programming, particularly in previously implanted ICDs, remains inconsistent throughout the United States, with significant provider-dependent variability. We developed an institutionally standardized ICD reprogramming protocol for primary prevention ICDs utilizing high detection rates and long detection intervals, then prospectively evaluated outcomes in patients programmed with this protocol compared to a historical cohort. Read More

View Article and Full-Text PDF

Heart Failure and Patient-Reported Outcomes in Adults With Congenital Heart Disease from 15 Countries.

J Am Heart Assoc 2022 May 26;11(9):e024993. Epub 2022 Apr 26.

Centre for Person-Centred Care (GPCC) University of Gothenburg Gothenburg Sweden.

Background Heart failure (HF) is the leading cause of mortality and associated with significant morbidity in adults with congenital heart disease. We sought to assess the association between HF and patient-report outcomes in adults with congenital heart disease. Methods and Results As part of the APPROACH-IS (Assessment of Patterns of Patient-Reported Outcomes in Adults with Congenital Heart disease-International Study), we collected data on HF status and patient-reported outcomes in 3959 patients from 15 countries across 5 continents. Read More

View Article and Full-Text PDF

Establishment of a Dedicated Inherited Cardiomyopathy Clinic: From Challenges to Improved Patients' Outcome.

J Am Heart Assoc 2022 May 26;11(9):e024501. Epub 2022 Apr 26.

Hartford HealthCare, Heart and Vascular Institute Hartford CT.

Background Inherited cardiomyopathies (ICs) are relatively rare. General cardiologists have little experience in diagnosing and managing these conditions. International societies have recognized the need for dedicated IC clinics. Read More

View Article and Full-Text PDF

Submammary placement of implantable cardioverter defibrillators: a Singapore plastic surgeon experience.

Singapore Med J 2022 01;63(1):47-50

Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, Ng Teng Fong General Hospital, Singapore.

The use of implantable cardioverter defibrillators (ICDs) in young women has been increasing in recent years owing to greater awareness about inherited cardiac conditions that increase the risk of sudden death. Traditional placement of ICDs in the infraclavicular region among young women often leads to visible scars, a constant prominence that causes irritation from purse or bra straps and can result in body image concerns and device-related emotional distress. In this case series, two women with long QT syndrome required placement of ICDs for prevention of sudden cardiac death. Read More

View Article and Full-Text PDF
January 2022

Device runtime and costs of cardiac resynchronization therapy pacemakers - a health claims data analysis.

Ger Med Sci 2022 4;20:Doc02. Epub 2022 Mar 4.

Institute of Social Medicine and Epidemiology, University of Lübeck, Germany.

This study investigates the runtime and costs of biventricular defibrillators (CRT-D) and biventricular pacemakers (CRT-P). Accurate estimates of cardiac resynchronization therapy (CRT) device runtime across all manufactures are rare, especially for CRT-P. Health claims data of a large nationwide German health insurance was used to analyze CRT device runtime. Read More

View Article and Full-Text PDF

Impact of right ventricular pacing site on the subcutaneous ICD sensing-a step towards personalised device therapy?

J Interv Card Electrophysiol 2022 Apr 23. Epub 2022 Apr 23.

Cardiac Rhythm Management Research Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Background: Patients with an existing subcutaneous implantable cardiac defibrillator (S-ICD) may develop a pacing indication. When transvenous pacing is not feasible, combining an S-ICD and a leadless pacemaker (LP) can be a reasonable option. There are reports of concomitant use of both devices. Read More

View Article and Full-Text PDF

History and evolution of pacing and devices.

Heart 2022 05;108(10):794-799

Cardiology, St George's University of London, London, UK

Cardiac implanted electronic devices are commonplace in the modern practice of cardiology. This article reviews the history of the development of these technologies, with particular reference to the role played by UK physicians and members of the British Cardiovascular Society. Key breakthroughs in the treatment of heart block, ventricular arrhythmia and heart failure are presented in their historical and contemporary context so that the reader might look back on the incredible progress and achievements of the last 100 years and also look forward to what may be achieved in the coming decades. Read More

View Article and Full-Text PDF

Advanced heart failure and cardiac arrhythmia in a young adult survivor of childhood cancer.

Vnitr Lek 2022 ;68(E-1):22-26

The goal of this case report is to describe the young childhood cancer survivor who was treated for nonHodgkin lymphoma with chemotherapy containing anthracycline doxorubicin and who developed symptoms of serious cardiovascular damage 27 years after diagnosis of cancer. The patient is in longterm complete remission of the lymphoma. He started guideline medical therapies for chronic heart failure and had a cardioverter defibrillator implanted for primary prevention of sudden cardiac death. Read More

View Article and Full-Text PDF

Clinical Profile, Arrhythmias, and Adverse Cardiac Outcomes in Emery-Dreifuss Muscular Dystrophies: A Systematic Review of the Literature.

Biology (Basel) 2022 Mar 30;11(4). Epub 2022 Mar 30.

Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, 41124 Modena, Italy.

Cardiolaminopathies are a heterogeneous group of disorders which are due to mutations in the genes encoding for nuclear lamins or their binding proteins. The whole spectrum of cardiac manifestations encompasses atrial arrhythmias, conduction disturbances, progressive systolic dysfunction, and malignant ventricular arrhythmias. Despite the prognostic significance of cardiac involvement in this setting, the current recommendations lack strong evidence. Read More

View Article and Full-Text PDF

Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population.

Turk Kardiyol Dern Ars 2022 Apr;50(3):182-191

CRT Survey-II Investigators.

Objective: Cardiac resynchronization therapy is the guideline-directed treatment option in selected heart failure with reduced left ventricular ejection fraction patients. Data regarding the contemporary clinical practice of cardiac resynchronization therapy in Turkey have been published recently. This sub-study aims to compare clinical and periprocedural characteristics between cardiac resynchronization therapy upgrade and de novo implantations. Read More

View Article and Full-Text PDF

Arrhythmogenic Right Ventricular Cardiomyopathy.

JACC Clin Electrophysiol 2022 Apr;8(4):533-553

Center for Cardiovascular Innovation, Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada; Victorian Heart Institute, Monash University, Clayton, Victoria, Australia.

Arrhythmogenic right ventricular cardiomyopathy (ARVC) encompasses a group of conditions characterized by right ventricular fibrofatty infiltration, with a predominant arrhythmic presentation. First described in the late 1970s and early 1980s, it is now frequently recognized to have biventricular involvement. The prevalence is ∼1:2,000 to 1:5,000, depending on geographic location, and it has a slight male predominance. Read More

View Article and Full-Text PDF

Implantable Cardioverter Defibrillator in Primary and Secondary Prevention of SCD-What We Still Don't Know.

J Cardiovasc Dev Dis 2022 Apr 16;9(4). Epub 2022 Apr 16.

Department of Cardiology, Emergency Clinical Hospital "Sf. Spiridon", 700111 Iasi, Romania.

Implantable cardioverter defibrillators (ICDs) are the cornerstone of primary and secondary prevention of sudden cardiac death (SCD) all around the globe. In almost 40 years of technological advances and multiple clinical trials, there has been a continuous increase in the implantation rate. The purpose of this review is to highlight the grey areas related to actual ICD recommendations, focusing specifically on the primary prevention of SCD. Read More

View Article and Full-Text PDF